The S-3 shelf filed 2 days before this earnings release is the dominant signal — the company is telegraphing a desperate capital raise. With $8.2M cash and a $9.1M quarterly burn, the company has <9 months of runway. Expect a dilutive offering within weeks. Short sellers should monitor for a priced offering announcement; any bounce on regulatory milestones is a selling opportunity given the dilution overhang.
Price Chart
Executive Summary
Co-Diagnostics reported Q1 2026 revenue of $0.15M (up from $0.05M YoY) and a net loss of $9.1M ($4.06/share), widening from a $7.5M loss in Q1 2025. Cash burn continues, with cash dropping to $8.2M from $11.9M at year-end 2025. The company is advancing regulatory milestones (CDSCO license in India, FDA 510(k) submission prep) but remains pre-commercialization with no clear path to profitability. The S-3 shelf filed 2 days ago for up to $150M (over 20x market cap) signals extreme potential dilution, overriding any operational progress.
Key Financial Metrics
Key Facts
- Q1 2026 revenue of $0.15M vs $0.05M YoY, but gross loss of $47,814 vs gross profit of $28,687 in Q1 2025
- Net loss widened to $9.1M ($4.06/share) from $7.5M ($7.05/share) in Q1 2025
- Cash and cash equivalents fell to $8.2M from $11.9M at Dec 31, 2025 — a 31% quarterly cash burn
- S-3 shelf filed May 12, 2026 for up to $150M in securities — over 20x the $6M market cap
- Operating loss of $9.2M vs $8.6M in Q1 2025, driven by R&D spending on clinical studies
- Adjusted EBITDA loss of $8.7M vs $7.4M in Q1 2025
- Shares outstanding surged to 3.6M from 2.1M at Dec 31, 2025 — 72% dilution in 5 months
- Company expects continued investment in clinical development with no timeline to profitability
Financial Impact
Cash burn rate of ~$3.7M/quarter with only $8.2M cash remaining; $150M shelf represents potential 25x dilution at current market cap
Risk Factors
- Imminent dilutive offering under the $150M shelf — potential for 90%+ dilution at current prices
- Cash runway of <9 quarters at current burn rate without additional capital
- No approved products generating revenue; all platform tests still under FDA review
- Negative gross margin (-33%) in Q1 2026 vs positive gross margin in Q1 2025
- Accumulated deficit of $89.5M with no path to profitability
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001493152-26-023059 |
| Document: form8-k.htm | 0001493152-26-023059 |
| Document: 0001493152-26-023059-index-headers.html | 0001493152-26-023059 |
| Document: 0001493152-26-023059-index.html | 0001493152-26-023059 |
| Document: 0001493152-26-023059.txt | 0001493152-26-023059 |
| 8-K Data (Synthetic) | 0001493152-26-023059 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 1d ago | DEF 14A | $0.5473 | awaiting T+20 | — | $0.4689 (+14.32%) |
Oct 15, 2026 12d ago | 8-K/A | $0.7151 | awaiting T+20 | — | $0.4689 (+34.43%) |
Oct 13, 2026 14d ago | 8-K | $1.07 | awaiting T+20 | — | $0.4689 (+55.97%) |
Sep 16, 2026 5w ago | 8-K | $0.9408 $1.07 | ▲ +13.20% | ▲ +10.02% | $0.4689 (−50.16%) |
Sep 16, 2026 5w ago | 8-K | $0.9408 $1.07 | ▲ +13.20% | ▲ +10.02% | $0.4689 (−50.16%) |
Sep 4, 2026 7w ago | DEFA14A | $1.16 $1.10 | ▼ −5.17% | ▼ −5.77% | $0.4689 (−59.58%) |
Sep 2, 2026 7w ago | EFFECT | $1.16 $1.07 | ▲ +7.76% | ▲ +7.68% | $0.4689 (+59.58%) |
Jul 31, 2026 12w ago | 8-K | $1.44 $1.21 | ▲ +15.97% | ▲ +18.96% | $0.4689 (+67.44%) |
Jul 27, 2026 13w ago | 424B5 | $1.41 $1.23 | ▲ +12.77% | ▲ +16.15% | $0.4689 (+66.74%) |
Jun 1, 2026 21w ago | EFFECT | $6.20 $3.10 | ▲ +50.00% | ▲ +48.70% | $0.4689 (+92.44%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers